One allosteric inhibitor of SHP2, SHP099, demonstrated anti-tumor activity and increased immune response in mice inoculated with CT-26 colon carcinoma in a manner that was enhanced by anti-PD1 therapy [129]. This evidence concerns the gene PDCD1 and neoplasm.